8-K: Adicet Bio Initiates Phase 1 Clinical Trial Enrollment for ADI-001 in Autoimmune Diseases

Adicet Bio has opened enrollment for its Phase 1 clinical trial of ADI-001 in autoimmune diseases, including lupus nephritis, with plans to expand to other indications in the fourth quarter of 2024.

Summary

• Adicet Bio has announced the start of enrollment for its Phase 1 clinical trial of ADI-001 in autoimmune diseases.
• The trial will initially focus on patients with lupus nephritis (LN), with plans to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) in the fourth quarter of 2024.
• The company expects to report preliminary clinical data from the trial in the first half of 2025.
• The FDA has granted Fast Track Designation to ADI-001 for the treatment of relapsed/refractory class III or class IV LN.
• The Phase 1 study has three arms, with LN and SLE patients in one arm, SSc patients in a second arm, and AAV patients in a third arm.
• Enrolled patients will receive a single dose of ADI-001, with a 28-day dose-limiting toxicity window.
• Response and safety assessments will be conducted on Day 28 and during the follow-up period on months 3, 6, 9, 12, 18, and 24.
• The primary objective of the study is to evaluate the safety and tolerability of ADI-001.
• Secondary objectives include measuring cellular kinetics, pharmacodynamics, changes in autoantibody titers, and disease activity scores.

Sentiment

Score: 7

Explanation: The document is positive due to the initiation of a clinical trial and the FDA's Fast Track Designation, but it also acknowledges the inherent risks and uncertainties in drug development.

Positives

• The initiation of the Phase 1 clinical trial for ADI-001 in autoimmune diseases is a positive step for the company.
• The FDA's Fast Track Designation for ADI-001 in lupus nephritis suggests potential for expedited regulatory review.
• The company plans to report preliminary clinical data in the first half of 2025, which could provide valuable insights into the efficacy of ADI-001.
• The favorable safety profile, cellular kinetics and B cell depletion demonstrated with ADI-001 clinical experience to date, positions ADI-001 to potentially bring a paradigm shift in the treatment of autoimmune diseases.

Risks

• The company's ability to execute on its strategy, including obtaining regulatory approvals, is subject to risks.
• Positive results from early clinical studies may not be predictive of future results.
• Clinical studies may fail to demonstrate adequate safety and efficacy.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable.
• The company's ability to meet production and product release expectations is not guaranteed.
• Global economic conditions and public health crises could disrupt the company's business and financial results.

Future Outlook

Adicet plans to expand enrollment to include SLE, SSc, and AAV patients in the fourth quarter of 2024 and report preliminary clinical data in the first half of 2025. The company aims to demonstrate the potential of ADI-001 to bring a paradigm shift in the treatment of autoimmune diseases.

Management Comments

• Francesco Galimi, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Adicet Bio, stated that the favorable safety profile, cellular kinetics and B cell depletion demonstrated with ADI-001 clinical experience to date, positions ADI-001 to potentially bring a paradigm shift in the treatment of autoimmune diseases.

Industry Context

This announcement is significant in the context of the growing interest in cell therapies for autoimmune diseases. Adicet's approach using allogeneic gamma delta T cells is a novel approach in this space, and the results of this trial will be closely watched by the industry.

Comparison to Industry Standards

• The use of allogeneic gamma delta T-cell therapy is a relatively new approach compared to traditional CAR T-cell therapies, which often use autologous cells.
• Companies like Kite Pharma and Novartis have focused on autologous CAR T-cell therapies for cancer, while Adicet is exploring allogeneic options for both cancer and autoimmune diseases.
• The trial design, with a single dose and follow-up assessments over 24 months, is consistent with early-stage clinical trials for cell therapies.
• The focus on multiple autoimmune indications in a single trial is a unique approach, as many companies focus on one indication at a time.

Stakeholder Impact

• Shareholders may react positively to the initiation of the clinical trial and the potential for future data releases.
• Patients with autoimmune diseases may benefit from the development of new treatment options.
• Employees of Adicet Bio are likely to be involved in the execution of the clinical trial.
• The company's suppliers and partners may be impacted by the progress of the trial.

Next Steps

• Adicet will continue to enroll patients with lupus nephritis (LN).
• The company plans to initiate enrollment of patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) in the fourth quarter of 2024.
• Adicet will report preliminary clinical data from the trial in the first half of 2025.

Key Dates

Keywords

ADI-001, autoimmune diseases, clinical trial, lupus nephritis, systemic lupus erythematosus, systemic sclerosis, ANCA associated vasculitis, gamma delta T cell therapy, FDA Fast Track Designation, biotechnology